




RealRate

PHARMACEUTICAL 2017

Biomarin Pharmaceutical INC
Rank 180 of 308

B:OMARIN®



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Biomarin Pharmaceutical INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biomarin Pharmaceutical INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 48% points. The greatest weakness of Biomarin Pharmaceutical INC is the variable Assets, Current, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is 229%, being 16% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	1,421,791
Cost of Goods Sold	209,620
Intangible Assets	750,819
Liabilities, Current	439,310
Liabilities, Non-Current	42,034
Other Assets	1,052,312
Other Compr. Net Income	-8,217
Other Expenses	982,989
Other Liabilities	776,071
Other Net Income	11,878
Other Revenues	-1,116,854
Property and Equipment	798,768
Research and Development	661,905
Selling, General and Administrative Expense	476,593

Output Variable	Value in 1000 USD
Assets	4,023,690
Liabilities	1,257,415
Expenses	2,331,107
Revenues	-1,116,854
Stockholders Equity	2,766,275
Net Income	-3,436,083
Comprehensive Net Income	-3,440,192
BaseVar	4,374,580
ECR before Limited Liability	98%
Economic Capital Ratio	229%